This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Csl Limited, Kenta Biotech Ag. Active years: 2009-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Munsingen, CH (2012)
- Münsingen, CH (2009 - 2016)
- Muensingen, CH (2019 - 2023)
Company Filing History:
Years Active: 2009-2023
Title: Martin A. Imboden: Innovator in High Density Lipoprotein Formulations
Introduction
Martin A. Imboden, an accomplished inventor based in Munsingen, Switzerland, has made significant contributions to the field of medical formulations. With a total of seven patents under his name, he has focused on innovative solutions to address various health concerns, particularly those related to cardiovascular health.
Latest Patents
One of his latest patents features a reconstituted high density lipoprotein (HDL) formulation aimed at reducing toxicity levels. This formulation comprises an apolipoprotein, such as ApoAI or a fragment thereof, a lipid, and a detergent. The unique aspect of this invention is that it maintains the detergent at a level that is approximately 5-50% below the threshold that could induce liver toxicity in humans. The optimal lipid used in this formulation is phosphatidylcholine, at a concentration of about 30-50 g/L, and the molar ratio of apolipoprotein to lipid is best maintained between 1:40 and 1:75. This formulation is particularly beneficial in treating various cardiovascular-related ailments, including hypercholesterolemia, hypocholesterolemia, acute coronary syndrome (ACS), atherosclerosis, and myocardial infarction.
Career Highlights
Throughout his career, Martin A. Imboden has been associated with prominent companies such as CSL Limited and Kenta Biotech AG. His expertise in the field has propelled advancements in medical formulations, rendering tangible improvements in treatment options for patients.
Collaborations
Imboden has had the opportunity to work alongside notable professionals, including Samuel Wright and Reinhard Franz Bolli. These collaborations have undoubtedly enriched his research and innovative endeavors, further enhancing the impact of his contributions to healthcare.
Conclusion
Martin A. Imboden exemplifies the spirit of innovation within the healthcare sector. His dedication to developing safe and effective formulations for high density lipoproteins has the potential to significantly affect public health and improve various medical treatments. With numerous patents to his name, his work continues to inspire future advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile